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Abstract
Introduction: Congenital hyperinsulinism of Infancy (CHI) comprises heterogenic defects of insulin secretion with diverse molecular 
aetiology, histological features, severity of symptoms, and response to pharmacotherapy. 
The study aimed to establish the first clinical characteristics of Polish patients with CHI and to propose a novel clinical algorithm allowing 
the prioritisation of genetic and radiology studies, based on patient’s characteristics and response to pharmacotherapy.
Material and methods: Thirty-one patients with CHI were recruited from five reference centres in Poland. Clinical and biochemical 
parameters were statistically evaluated and compared to those of a control group (n = 30).
Results: CHI predisposes to increased birth weight (p = 0.004), lower Apgar score (p = 0.004), perinatal complications (74%), and neu-
rological implications (48%). Diagnostic process and therapy were inconsistent. A trial of pharmacotherapy was applied in 21 patients 
(68%), and diagnostic imaging with 18F-L-DOPA PET was performed in only 3. Eighteen patients (58%) were surgically treated, including 
8 infants (44%) aged less than 2 months. Depending on the type of resection, further hypoglycaemia was observed postoperatively in 50% 
(n = 9) and hyperglycaemia in 39% (n = 7) of cases. Based on foregoing results, a clinical algorithm was proposed.
Conclusions: Standardisation of clinical management with the use of pharmacotherapy, genetic screening, and diagnostic imaging will 
allow the optimisation of therapy and minimisation of treatment complications. (Endokrynol Pol 2015; 66 (4): 322–328)
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Streszczenie
Wstęp: Wrodzony hiperinsulinizm (CHI) obejmuje heterogenną grupę zaburzeń sekrecji insuliny przez komórki β trzustki i charakteryzuje 
się zróżnicowaną etiologią molekularną, obrazem histopatologicznym, nasileniem objawów oraz odpowiedzią na leczenie farmakologicz-
ne. Celem pracy było stworzenie charakterystyki klinicznej polskich pacjentów z wrodzonym hiperinsulinizmem oraz podjęcie próby 
stworzenia algorytmu diagnostyczno-terapeutycznego, umożliwiającego priorytetyzację badań genetycznych i obrazowych w zależności 
od obrazu klinicznego, wyników badań laboratoryjnych oraz odpowiedzi na leczenie farmakologiczne.
Materiał i metody: Do badania włączono 31 pacjentów z rozpoznaną hipoglikemią w przebiegu hiperinsulinizmu z 5 ośrodków w Polsce. 
Analizę danych klinicznych oraz parametrów biochemicznych pacjentów hipoglikemią odniesiono do 30-osobowej grupy kontrolnej.
Wyniki: Pacjenci z CHI charakteryzowali się znacznie wyższą masą urodzeniową (p = 0,004), niższą oceną uzyskaną w okołoporodowej 
skali Apgar (p = 0,004), częstszymi komplikacjami okołoporodowymi (74%) oraz powikłaniami neurologicznymi (48%). Przeprowadzona 
w badanej grupie diagnostyka była niespójna. U 21 pacjentów (68%) włączono leczenie za pomocą Diazoksydu, a u 3 pacjentów (9,7%) 
wykonano diagnostykę obrazową przy użyciu 18F-L-DOPA PET. Wśród 18 (58%) pacjentów leczonych chirurgicznie u 8 (44%) resekcję 
wykonano w wieku poniżej 2. miesiąca życia. Pooperacyjnie w zależności od typu wykonanej operacji obserwowano hipoglikemię 
u 50% (n = 9), a hiperglikemię u 39% (n = 7). Na podstawie uzyskanych wyników zaproponowano pierwszy w Polsce algorytm diagno-
styczno-terapeutyczny.
Wnioski: Ujednolicenie schematu postępowania diagnostycznego-terapeutycznego z wykorzystaniem wszystkich dostępnych metod 
umożliwi zapobieganie kolejnym epizodom choroby, oraz zminimalizuje komplikacje wynikające z leczenia. 
(Endokrynol Pol 2015; 66 (4): 322–328)
Słowa kluczowe: wrodzony hiperinsulinizm; Diazoksyd; 18-F-DOPA-PET
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Introduction
Congenital Hyperinsulinism of Infancy (CHI) is the 
most common cause of permanent hypoglycaemia in 
children. It comprises a heterogenic group of insulin 
secretion defects, and it is characterised by diverse 
molecular aetiology, histological features, severity of 
symptoms, and response to pharmacological treat-
ment [1–3].
Diagnosis and therapy of CHI is one of the most 
difficult aspects of contemporary endocrinology and 
diabetology. Although it is relatively easy to establish 
this clinical diagnosis, the management consists of 
many problems and pitfalls in daily care. 
Symptoms of hypoglycaemia are diverse, from 
completely unnoticeable or very subtle to severe attacks 
causing irreversible damage in the central nervous 
system [2]. Diagnosis of CHI includes clinical assess-
ment, laboratory tests, genetic studies, and nuclear 
imaging [2].
Laboratory diagnostic criteria include hypoketotic 
hypoglycaemia (below 45 mg/dL, 2.6 mmol/L) with 
detectable serum insulin level. There are no normal 
limits for blood insulin level. The “Normal” insulin 
level for normoglycaemia is usually abnormal in the 
presence of hypoglycaemia [4]. Required high intra-
venous glucose infusions (> 8 mg/kg/min, normal 
range 4–6 mg/kg/min) are also typical for insulin 
secretion defects. 
A trial of diazoxide treatment and clinical 
observation of glucose level is the first stage of 
CHI management, and its result should influence 
further therapeutic decisions. CHI responding to 
pharmacotherapy with diazoxide requires no fur-
ther investigations, while in the drug-resistant type 
genetic analysis and radiology imaging should be 
considered.
Molecular analysis introduced in the last decade 
has revolutionised diagnosis and clinical care of CHI 
[3, 5, 6]. In many centres identification of the genetic 
background of CHI has become strategic in planning 
further therapy: conservative treatment or radical 
surgical resection. Detection of particular mutations 
and phenotypes indicates the expected response to 
pharmacotherapy, morphology of pancreatic lesions 
(diffuse or focal forms), and allows introduction of the 
optimal type of surgical treatment. Mutations in eight 
genes (ABCC8, KCNJ11, GLUD1, GCK, HNF4A, HADH, 
SLC16A1, and UCP2) have been described as related to 
CHI. Mutations in these genes are usually recognised 
in 50–80% of patients, depending on the screened 
population and the applied genetic methods [3, 7–9]. 
In the remaining 20–50% of patients the genetic cause 
of hypoglycaemia is still unknown [1, 7]. Unfortunately, 
molecular studies are not fully available in Poland at 
the moment. 
Imaging with use of 18F-DOPA PET, introduced to 
medical practice in the year 2003, complements molecu-
lar studies and allows differentiation between focal and 
diffuse forms of CHI. 
In Poland there are as yet no national guidelines 
for clinical management of CHI. Diagnosis and 
therapy is based solely on physicians experience 
and international literature. In the study we aimed 
to analyse a Polish cohort with CHI and to propose 
a current diagnostic algorithm in order to optimise 
medical care of CHI.
Material and methods
In the study 31 patients with hypoglycaemia with 
hyperinsulinism were recruited from five diabetol-
ogy, endocrinology, and metabolic centres in Poland. 
Analysis included patients diagnosed with CHI in the 
years 2000–2012. 
A control group (n = 30) without hypoglycaemia, 
diabetes mellitus, or other carbohydrate metabolism 
disturbances was selected from healthy patients, in 
which the exact diagnostic process as in hypoglycaemia 
patients was applied. Patients recruited to the control 
group were admitted to hospital with hypoglycaemia 
suspicion due to general, unspecific complaints such as 
general malaise, poor appetite, or fainting episodes. In 
these patients, after detailed assessment no hypoglycae-
mia was noted. This group was slightly older compared 
to the CHI group, due to an insufficient number of pa-
tients at the age of infancy allowing us to perform the 
planned diagnostic process. Hypoglycaemia, diabetes 
mellitus, and other carbohydrate metabolism distur-
bances were excluded in the control group. 
The following aspects were analysed: clinical charac-
teristics of CHI patients, perinatal history, biochemical 
parameters, applied diagnostic tools, treatment, and 
complications. Diagnostic criteria for CHI included: 
nonketotic hypoglycaemia (< 45 mg/dL) with detect-
able serum insulin concentration, increase of glucose 
level (> 30 mg/dL) during glucagon stimulation 
test, and required intravenous glucose infusion rate 
> 8 mg/kg/min. The performed controlled fasting 
test lasted, depending on the age at diagnosis, from 8 
(< 6 months old) to 24 hours. In 8 patients no prolonged 
(> 8 hours) fasting studies were performed because 
severe hypoglycaemia occurred during normal feeding 
regime (Table I).
Statistical analysis was performed with MATLAB 
R2013a software. It included Fisher test, Manna-Whit-
ney U test, t-Student test, hierarchical cluster analysis, 
and Spearman correlation rank.
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Results
Clinical characteristics of patients with chi 
Hypoglycaemia was observed in 87% of patients ei-
ther just after birth (n = 23, 74%) or in the first year of 
life (n = 4, 13%). The mean lowest glucose level was 
17.3 ± 8.1 mg/dL (range 4-36 mg/dL). The most common 
symptoms included loss of consciousness (n = 25) and 
seizures (n = 24) (Fig. 1).
Based on Fisher test, neither age (p = 0.1) nor serum 
glucose level (p = 0.2) influenced particular symptoms 
of hypoglycaemia. 
Observed neurological complications in patients 
with CHI included epilepsy (n = 13, 42%), developmen-
tal delay (n = 9, 29%), and microcephaly (n = 2, 6%), 
while in only one patient from the control group a mild 
form of epilepsy was diagnosed. In patients present-
ing with seizures, a not statistically relevant tendency 
to subsequent epilepsy and developmental delay was 
observed. No correlation between age of first hypo-
glycaemia symptoms and neurological complications 
was observed.
Perinatal history 
Patients with CHI (n = 24, 77%), as in the control group 
(n = 21, 70%), were usually born at term. In hypogly-
caemia patients 10% were born by caesarean section 
compared to 7% in the control group. In 23 of CHI 
patients (74%) hypoglycaemia was noted immediately 
after birth, mainly as seizures or hypotonia (Fig. 2). In 
the control group no hypoglycaemia was noted after 
birth. Statistical analysis revealed that patients with CHI 
received significantly lower Apgar score in comparison 
to the control group (p = 0.004). 
Further analysis showed higher birth weight in CHI 
patients (3850 ± 725 g) compared to the control group 
(3306 ± 641 g) (p = 0.004). 
In 16 patients (52%) with hypoglycaemia foetal 
macrosomy was noted, compared to 5 patients (16%) 
from the control group (p = 0.034).
Subsequent analysis showed no correlation between 
birth weight and perinatal hypoglycaemia (p = 0.45). 
In CHI patients with increased birth weight a ten-
dency towards higher insulin level (33.75 ± 23.4 ulu/mL) 
as well as C-peptide level (3.81 ± 2.17 ng/dL) was 
observed. However, these trends were not statistically 
relevant (p = 0.1, p = 0.47, respectively). 
Table I. General characteristics of patients with hypoglycaemia 
and the control group
Tabela I. Ogólna charakterystyka pacjentów z hipoglikemią 
oraz grupy kontrolnej
Clinical parameter CHI patients  
(n = 31)
Control group  
(n = 30)
Male n = 12 (39%) n = 13 (43%)
Female n = 19 (61%) n = 17 (57%)
Mean age at the time of 
clinical investigations 
[months]
11.8 ± 33 (0–168) 95.3 ± 61 (6–190)
Mean lowest serum 
glucose level  
[mg/dL]
17.3 ± 8.1 (4–36) 67.6 ± 9,2 (49–80)
Hypoglycaemia 
symptoms
n = 31 (100%) n = 0 (0%)
Family history of 
hypoglycaemia
n = 7 (23%) n = 0 (0%)
Parental consanguinity n = 0 (0%) n = 0 (0%)
Perinatal  
hypoglycaemia
n = 23 (74%) n = 0 (0%)
Figure 1. Observed hypoglycaemia symptoms
Rycina 1. Obserwowane objawy hipoglikemii
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Biochemical parameters 
In CHI patients lower HbA1c and higher C-peptide and 
ammonia levels were observed. In 5 patients with CHI 
the ammonia level was higher than 100 ug/dL (range 
100–273 ug/dL). There was no difference between total 
cholesterol or triglyceride levels. 
Prolonged fasting studies showed higher lactic acid 
and lower pH level at the end of the test (Table II). 
Correlation analysis based on Spearman’s rank 
correlation coefficient revealed a positive correlation 
between fasting insulin and C-peptide levels (R = 0.72, 
p = 0.005). In addition, a negative correlation between 
fasting glucose and triglycerides levels (R = –0.83, 
p = 0.01) was observed.
Diagnosis and treatment
Molecular imaging with use of 18-F-DOPA-PET was 
performed in only three CHI patients (9.7%). Diffuse 
form was diagnosed in two patients, while a focus in 
the pancreatic head was observed in one patient.
A trial of diazoxide treatment was applied in 
21 patients (68%). In the remaining 10 patients no 
diazoxide was applied due to problematic access 
to medication and precipitous decision on surgical 
management. Good clinical response (no further 
hypoglycaemia) was observed in nine patients (43%), 
and no other treatment was applied. Insufficient 
response to pharmacotherapy was observed and 
surgical treatment was applied in 12 patients (57%) 
treated with diazoxide. Surgical treatment was also 
applied to 6 of the 10 remaining patients not treated 
with diazoxide. 
Besides diazoxide, offered pharmacotherapy in-
cluded octreotide (n = 8, 26%), GlucaGen (n = 10, 32%), 
and steroids (n = 4, 13%).
A diet based on low glycaemic index as well as 
frequent feeding regime was introduced in 27 patients 
(87%). 74% of patients (n = 23) required nighttime feed-
ing in order to prevent further hypoglycaemia. 
Surgical treatment was applied in 18 patients (58%). 
At the time of pancreatic resection the mean age of 
the patients was 10.5 months (range 1–54 months, 
SD = 16.8 months). However, surgery was performed 
at age of two months or less in eight patients (44%). 
Subtotal pancreatectomy was performed in 
16 patients (89%), although in 2 patients subsequent 
total pancreatectomy was required due to persistent 
hypoglycaemia, despite primary subtotal resection. 
In one patient selective focal resection was applied 
and in another one partial resection was performed. 
Analysis of postoperative histopathological descrip-
tions revealed diffuse forms in nine patients (50%) 
and focal forms in three patients (17%). In three 
patients the morphological picture was described as 
diffuse form with intensification in particular parts 
of pancreas, and in the three remaining patients the 
description was unclear. 
Clinical complications, depending on the type of re-
section, included: further hypoglycaemia (n = 9, 50%), 
hyperglycaemia (n = 7, 39%), and postoperative infec-
tion (n = 2, 11%). In four patients (22%) postoperative 
insulin therapy was required, and in five (28%) cases 
enzyme replacement therapy was needed. In a patient 
with focal resection no postoperative complications 
were observed (Table III). 
Discussion
Congenital hyperinsulinism most commonly occurs in 
the newborn period; however, it can also be observed 
in older children [2, 7, 10, 11]. Particularly in newborns 
hypoglycaemia symptoms can be very unspecific and 
difficult to observe. In the studied cohort mainly neu-
rological symptoms of hypoglycaemia were observed; 
however, also atypical symptoms such as apnoea, cyano-
sis, or poor feeding occurred. Nearly half of the studied 
newborns were macrosomic at birth due to increased 
insulin activity in foetal life, which also influenced more 
traumatic birth history and poor Apgar score compared 
to healthy controls. 
The characteristic metabolic profile observed during 
the performed diagnosis results from increased anabolic 
insulin activity [2, 10]. The observed strong correlation 
between insulin level and C-peptide confirms the diag-
nostic applicability of C-peptide measurements in CHI 
patients. Increased lactic acid level and decreased pH 
due to increased patient distress at the end of the study 
cast some doubt on the usefulness of these parameters 
in CHI diagnosis [7, 12, 13]. 
Figure 2. Perinatal complications in CHI patients and in the 
control group
Rycina 2. Komplikacje okołoporodowe u pacjentów z CHI oraz 
w grupie kontrolnej
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The strong negative correlation between fasting 
glucose level and serum triglycerides supports the ex-
pected negative effect of increased feeding frequency 
and increased simple carbohydrates intake in CHI 
patients. 
Assessment of clinical response to pharmacologi-
cal treatment is crucial in management of congenital 
hyperinsulinism [2]. The introduction of diazoxide in 
CHI therapy is the first-line treatment and determines 
further clinical management. 
Our study confirmed that in nearly half of patients 
a positive clinical response to diazoxide is observed [1, 
11]. Unfortunately, contrary to American and French 
observations [1, 7], a lack of therapy in 32% of the de-
scribed patients is reported. Moreover, in six patients 
surgical treatment was applied with no preceding 
diazoxide therapy due to unknown reasons. 
Pancreatic surgery was performed mainly in the 
first year of life. Moreover, in 44% of patients surgery 
was performed in the first two months of life, which 
could be an insufficient period for clinical observation 
and exclusion of transient forms [4]. 
Radiology imaging with use of 18-F-DOPA-PET was 
introduced into clinical practice in Poland in 2003. The 
available refund of this test by National Health Board 
has become an additional advantage over molecular 
studies. 
For many years surgical treatment was based ex-
clusively on total or subtotal pancreatectomy [14–16]. 
Currently, new diagnostic tools introduced into clinical 
practice enable the application of other, less traumatic 
types of surgical treatment [14, 17]. Subtotal pancre-
atic resection causes many complications, including 
hypo- and hyperglycaemia, whereas in focal resection 
all observed symptoms subside and no complications 
are observed.
In spite of increasing knowledge on pathogenesis 
and treatment of CHI, paediatricians, diabetologists, 
Table II. Biochemical parameters in CHI patients and in the control group
Tabela II. Parametry biochemiczne u pacjentów z CHI oraz w grupie kontrolnej
Parameter/studied group CHI patients (n = 31) Control group (n = 30)
    pMean Median Range Mean Median Range
HbA1c (%) 4.77 ± 0.47 4.91 4–5.43 5.33 ± 0.32 5.38 4.56–5.94 0.0078
Fasting C-peptide [ng/dL] 3.13 ± 2.19 3.12 0.5–5.74 1.13 ± 0.67 0.91 0.31–3.03 0.0007
Fasting glucose [mg/dL] 42.38 ± 21 38 19–87 77.97 ± 8.62 78.5 54–94 0.0000
Fasting insulin [ulU/mL] 24.62 ± 21.99 22 2.3–82 4.34 ± 2.99 3.4 0.5–10 0.0003
Prolonged fasting study — end of test:
Glucose [mg/dL] 30.62 ± 13.85 31 4–64 68.93 ± 10.57 72 49–88 0.0000
Insulin [ulU/mL] 15.09 ± 17.14 7.20 2.2–79 2.76 ± 2.47 1.75 1–10.1 0.0000
pH 7.35 ± 0.06 7.37 7.2–7.46 7.39 ± 0.04 7.39 7.3–7.45 0.0070
Lactic acid [mg/dL] 14.09± 16.75 9.7 0.9–56 2.16 ± 0.75 2.3 1–3.4 0.0003
Ammonia [ug/dL] 106.77 ± 72.29 93 23–273 33.10 ± 10.95 28 22–44 0.0003
Free fatty acids [mmol/L] 0.68 ± 0.85 0.34 0.05–3.7 0.7 ± 0.43 0.69 0.01–1.51 0.2792
Lipids:
Triglycerides [mg/dL] 82.94 ± 52.78 67 22–224 68.93 ± 29.97 66.00 33–185 0.7619
Total cholesterol [mg/dL] 161.8 ± 40.04 158 86–266 163.71 ± 30.17 162.50 112–253 0.6429
Table III. Postoperative complications in patients with CHI depending on type of surgery
Tabela III. Komplikacje pooperacyjne u pacjentów z CHI w zależności od typu operacji
Complications Total resection (n = 2) Partial resection (n = 1) Subtotal resection (n = 14) Focal resection (n = 1)
Hyperglycaemia n = 2 n = 0 n = 5 n = 0
Insulin therapy n = 2 n = 0 n = 2 n = 0
Enzyme replacement n = 2 n = 0 n = 5 n = 0
Infection n = 0 n = 0 n = 2 n = 0
Hypoglycaemia n = 0 n = 1 n = 8 n = 0
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and endocrinologists still have to make difficult clinical 
decisions. The applied treatment, in effect, may lead to 
other long-term complications such as diabetes. 
Depending on the available diagnostic tools vari-
ous schemes of diagnostics and treatment of CHI are 
applied in different centres. So far there are no clinical 
guidelines on the management of CHI available in Po-
land. CHI diagnosis in a Polish cohort may be further 
improved by recently introduced molecular studies 
(Medical University of Lodz, Jagiellonian University in 
Krakow, Medical University of Gdansk).
Below we present a proposal of a diagnostic algo-
rithm of CHI (Fig. 3).
After laboratory confirmation of hyperinsulinaemic 
hypoglycaemia (nonketotic hypoglycaemia < 45 mg/dL 
or < 2.6 mmol/L with detectable insulin level), frequent 
feeding regime and clinical observation of transient 
forms for minimal time of two months is required [7]. 
Following that, the trial of diazoxide treatment should 
be applied. Treatment usually lasts for five days in order 
to assess the clinical response (glycaemia > 55 mg/dL or 
> 3 mmol/L despite normal diet or prolonged fasting). 
In patients with good clinical response further observa-
tion is usually sufficient. In patients not responding to 
diazoxide further diagnosis based on molecular studies 
and 18-F-DOPA-PET should be performed. 18-F-DOPA-
PET is currently more accessible than genetic analysis 
in Poland; however, if genetic studies are available we 
recommend to do this first as it is less invasive. Ge-
netic studies include the genes ABCC8, KNCNJ11, and 
GCK. If diffuse form is confirmed in genetic analysis, 
no further imaging is needed. Focal forms require an 
additional PET scan (to describe its localisation) and 
limited pancreatectomy. 
In diffuse forms intensification of feeding and 
pharmacotherapy with somatostatin analogues should 
be applied. In the most severe cases total or subtotal 
resection should be performed.
Conclusions
In the study we presented the first analysis of phe-
notype, diagnosis, and treatment of Polish patients 
with congenital hyperinsulinism. CHI predisposes to 
increased birth weight and perinatal complications, 
and may lead to permanent brain injury. A diagnostic 
process of CHI is essential in further therapy, and the 
applied treatment influences subsequent complications. 
So far, diagnosis and therapy of congenital hyperinsu-
linism in Poland has been inconsistent. 
Standardisation of hypoglycaemia management 
with the use of all available methods including 
pharmacotherapy, molecular imaging, and genetic 
analysis will allow the prevention of subsequent 
hypoglycaemia episodes and will minimise treat-
ment complications. We believe that the proposed 
clinical algorithm will contribute to optimisation 
of medical care and prevent unnecessary subtotal 
or total pancreatic resections leading to irreversible 
physical disability. 
Figure 3. Proposed clinical algorithm of management of CHI
Rycina 3. Propozycja algorytmu diagnostyczno-terapeutycznego u pacjentów z CHI
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